Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/32—One oxygen, sulfur or nitrogen atom
  • C07D239/42—One nitrogen atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the present invention relates to a novel crystalline chemical compound and more particularly to a novel crystalline form of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid]calcium salt, hereinafter referred to as “the Agent”, and illustrated in Formula (I) hereinafter, which compound is an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG CoA reductase) and is useful as a pharmaceutical agent, for example in the treatment of hyperlipidemia, hypercholesterolemia and atherosclerosis, as well as other diseases or conditions in which HMG CoA reductase is implicated.
• the invention also relates to processes for the manufacture of the crystalline form, pharmaceutical compositions comprising the crystalline form and the use of the crystalline form in medical treatment.
• EPA 521471 discloses an amorphous (powder) form of the Agent, prepared by dissolving the corresponding sodium salt in water, adding calcium chloride and collecting the resultant precipitate by filtration.
• the Agent can be prepared in a second crystalline form from water without the need for an organic co-solvent.
• Form B obtained according to the present invention is substantially free from other crystal and non-crystal forms of the Agent.
• the term “substantially free from other crystal and non-crystal forms” shall be understood to mean that the desired crystal form contains less than 50%, preferably less than 20%, more preferably less than 10%, more preferably less than 5% of any other forms of the Agent.
• XRPD X-ray powder diffraction
• the collimated x-ray source was passed through an automatic variable divergence slit set at V20 (20 mm path length) and the reflected radiation directed through a 2 mm antiscatter slit and a 0.2 mm detector slit.
• the sample was exposed for 4 seconds per 0.02 degree 2-theta increment (continuous scan mode) over the range 2 degrees to 40 degrees 2-theta in theta-theta mode.
• the running time was 2 hours 6 minutes and 40 seconds.
• the instrument was equipped with a scintillation counter as detector. Control and data capture was by means of a DECpc LPv 433sx personal computer running with Diffrac AT (Socabim) software.
• the X-ray powder diffraction spectra of a typical sample of Form B is shown in FIG. 1 hereinafter.
• the 2-theta values of the X-ray powder diffraction pattern may vary slightly from one machine to another or from one sample of Form B to another, and so the values quoted are not to be construed as absolute. It will also be understood that the relative intensities of peaks may vary according to the orientation of the sample under test so that the intensities shown in the XRD trace included herein are illustrative and not intended to be used for absolute comparison.
• Form B may also be characterised by its infra-red (IR) spectrum, such as that carried out by the DRIFT (Diffuse-Reflectance Infrared Fourier Transform Spectroscopy) technique.
• IR infra-red
• DRIFT Diffuse-Reflectance Infrared Fourier Transform Spectroscopy
• a DRIFT spectrum of Form B is shown in Example 1 hereinafter. The spectrum was acquired using 2% w/w (in powdered KBr) over the 4,000-400 cm-1 spectral range on a Nicolet Magna 860 ESP FT-IR spectrometer. Spectral acquisition conditions were 2 cm-1 digital resolution, 64 background scans (KBr only) and 64 sample (2% sample mixed with KBr) scans.
• DRIFT spectra may be influenced by the particle size of the sample being examined.
• the spectrum for Form B shown hereinafter was obtained with a sample which had been crushed to a fine powder. Repeated samples, or those with an alternative sample preparation may give DRIFT spectra which vary in resolution, although the peak position frequency therein will be unchanged.
• Form B may also be characterised by other analytical techniques known in the art.
• Form B is obtained in a hydrated form with, for example, a water content of about 9-10% w/w, for example about 9% w/w.
• Form B may be crystallised from a saturated solution of the Agent in aqueous [(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid]sodium salt (hereinafter referred to as ‘Sodium Salt’).
• the amorphous form of the Agent is used as starting material and may be obtained, for example, as described in EPA 521471.
• the sodium salt may be prepared as described in WO 00/49014 and in Example 1 hereinafter.
• a process for the manufacture of a crystalline hydrated form of a compound of formula (I) which comprises forming crystals from a saturated solution of compound of formula (I) in aqueous bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid]sodium salt.
• a further aspect of the present invention provides a process for the manufacture of a crystalline hydrated form of a compound of formula (I) which comprises forming crystals from a saturated solution of the amorphous form of the compound of formula (I) in aqueous bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid]sodium salt.
• Saturation of the sodium salt solution with the Agent means addition of, for example the amorphous form to the sodium salt solution until the solution is saturated with respect to the amorphous form. Further amorphous form is added to maintain the saturation once crystallisation of Form B has started.
• the process of the invention is conveniently carried out between 20 and 45° C., more conveniently between 30 and 45° C., even more conveniently between 37 and 43° C., and preferably at about40° C.
• Form B may also be formed by seeding an aqueous solution or slurry of the amorphous form of the Agent, or by prolonged stirring of a solution of the amorphous form.
• a further feature of the invention is a method of treating a disease condition wherein inhibition of HMG CoA reductase is beneficial which comprises administering to a warm-blooded mammal an effective amount of Form B of the Agent.
• the invention also relates to the use of Form B in the manufacture of a medicament for use in a disease condition.
• the compound of the invention may be administered to a warm-blooded animal, particularly a human, in need thereof for treatment of a disease in which HMG CoA reductase is implicated, in the form of a conventional pharmaceutical composition. Therefore in another aspect of the invention, there is provided a pharmaceutical composition comprising Form B in admixture with a pharmaceutically acceptable carrier.
• compositions may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, topical, parenteral, buccal, nasal, vaginal or rectal administration or by inhalation.
• the Agent may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solution or suspensions or sterile emulsions.
• a preferred route of administration is oral.
• the Agent will be administered to humans at a daily dose in, for example, the ranges set out in EPA 521471.
• the daily doses may be given in divided doses as necessary, the precise amount of the Agent received and the route of administration depending on the weight, age and sex of the patient being treated and on the particular disease condition being treated according to principles known in the art.
• a process for the manufacture of a pharmaceutical composition containing Form B as active ingredient which comprises admixing Form B together with a pharmaceutically acceptable carrier.
• Form B has value as a processing aid for isolation of the amorphous form of the Agent.
• a process for formation of amorphous bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid]calcium salt comprising isolation of Form B as hereinbefore defined from a solution and subsequent conversion to the amorphous form.
• a process for formation of amorphous bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid]calcium salt comprising mixing a solution containing [(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid]calcium salt with a slurry of Form B in water, isolation of Form B and subsequent conversion of the isolated form B to the amorphous form, wherein Form B is as hereinbefore defined.
• the process for isolation of form B is conveniently carried out between 20 and 45° C., more conveniently between 30 and 45° C., even more conveniently between 37 and 43° C., and preferably at about 40° C.
• the solution containing [(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid]calcium salt is conveniently a waste solution such as a mother liquor solution from a process for formation and isolation of amorphous bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid]calcium salt from the corresponding sodium salt and calcium chloride.
• the Form B isolated from this process is of high purity, for example >90% on dry weight basis, preferably >95%, more preferably >99%.
• the quantity of Agent in the slurry of form B is conveniently approximately 15 mol % of that contained in the waste solution.
• the slurry and the waste solution are conveniently at a concentration of approximately 7 mg/ml.
• Form B as hereinbefore defined
• Form B as a processing aid for isolation of amorphous bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid]calcium salt.
• Form B as hereinbefore defined
• Form B as hereinbefore defined as an intermediate in the a manufacture of amorphous bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid]calcium salt.
• Form B-1 An XRD trace of Form B-1 is shown in Example 2.
• Form B-1 is produced by the removal of water from the crystal lattice of Form B. Upon dehydration, the long-range structure of Form B is retained in Form B-1, but Form B-1 has only limited short-range order.
• Form B-1 may be formed by heating a sample of Form B to 60° C. or by storing a sample of Form B at 0% Relative Humidity (RH) using equipment such as a DVS (Dynamic Vapour Sorption) instrument, for example a Surface Measurement Systems DVS — 1, as described in Example 2.
• Form B-1 may be converted back to Form B by appropriate exposure to water, for example by slurrying in water.
• Form B-1 demonstrates a distinct XRD pattern in comparison to that of Form B.
• the XRD pattern of Form B-1 may be determined by the method hereinbefore described for Form B.
• a ‘dehydrated hydrate’ form of the Agent having an X-ray powder diffraction pattern with peaks at 2-theta (2 ⁇ ) 4.4, 7.7, 9.0 and 20.7 at 0% RH.
• a ‘dehydrated hydrate’ of the Agent having an X-ray powder diffraction pattern with peaks at 2-theta (2 ⁇ ) 4.4, 9.0 and 20.7 at 0% RH.
• Form B-1 Exposure of Form B-1 to humidities above 0% RH allows water to re-enter the crystal lattice to a level dictated by the RH of the environment.
• water vapour does not easily reorder the structure to reproduce Form B, hence the material continues to lack short-range order and water is easily lost on lowering the relative humidity.
• the absorption and desorption of water may lead to small shifts in the XRD peaks.
• a DRIFT spectrum of Form B-1 is included in Example 2 hereinafter.
• the experimental conditions were as described hereinbefore for Form B, except that the sample was gently crushed.
• Aqueous sodium hydroxide (8% w/w, 27.2 ml) was added to a stirred mixture of [(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5)-3,5-dihydroxyhept-6-enoic acid]methylamine salt (30 g) in purified water (234 ml) at 20° C. and the mixture was stirred for 15 min. The mixture may be filtered if necessary to remove insoluble material. The mixture was concentrated under reduced pressure at ⁇ 40° C. until 142 ml of distillate collected.
• X-ray powder diffraction Peak Number 2 ⁇ d-Spacing Relative Intensity (>20%) 1 4.3 20.2 37.5 2 8.8 10.1 100 3 13.1 6.7 69.5 4 13.7 6.5 39.9 5 15.2 5.8 43.1 6 15.8 5.6 57.5 7 17.5 5.1 24.3 8 21.5 4.1 97.6 9 21.9 4.1 36.0 10 22.8 3.9 85.6 11 24.5 3.6 73.1 12 28.9 3.1 47.1
• the Form B sample was crushed to a fine powder before being homogeneously mixed with KBr.
• Other experimental conditioans have been described hereinbefore.
• a sample of Form B (approximately 6 mg) was dispensed into a glass sample pan and suspended from the balance of an SMS Dynamic Vapour Sorption (DVS) instrument.
• the DVS instrument was then used to hold at 0% RH, 30° C., overnight (after this time period the change in sample mass was ⁇ 0.002%/min over at least an hour).
• the sample was then analysed immediately by XRD. The sample was exposed for 0.40 sec per 0.0357° 2 ⁇ over the range 3° to 30° 2 ⁇ in continuous scan, theta-theta mode.
• the following trace is an example XRD trace of a sample of Form B-1 which has been stored at 0% RH. It will be appreciated that variations in the water content of the sample of Form B-1 will cause variations in the precise 2 ⁇ values described below, such variations in water content resulting for example by the conditions of storage of Form B-1. Peak Number 2 ⁇ d-Spacing Relative Intensity 1 4.4 20.0 100 2 7.7 11.4 26 3 9.0 9.9 58 4 20.7 4.3 22
• FIG. 3 is a comparison of the XRD traces of Forms B and B-1:
• the Form B may be converted to amorphous Agent as follows:
• a suspension of crystalline Form B (17.32 g) in acetonitrile (148 ml) was treated with water (70 ml) to form a solution at 20° C.
• Sodium chloride (18.8 g) was added to the solution and the pH is adjusted to 2.8-3.4 at 0° C. with aqueous hydrochloric acid and brine solution.
• FIG. 4 shows the XRD pattern for Form A, as described in WO 00/42024.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Vascular Medicine (AREA)
• Urology & Nephrology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Pyridine Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (3)

Applications Claiming Priority (5)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=34276833

Family Applications (4)

Family Applications After (3)

Country Status (32)

Cited By (11)

Families Citing this family (18)

Citations (8)

Family Cites Families (48)

• 2004
  • 2004-09-07 UY UY28501A patent/UY28501A1/es not_active Application Discontinuation
  • 2004-09-08 ES ES04768376T patent/ES2324042T3/es active Active
  • 2004-09-08 CN CN2004800308267A patent/CN1878760B/zh active Active
  • 2004-09-08 DK DK04768376T patent/DK1663989T3/da active
  • 2004-09-08 KR KR1020067004952A patent/KR20070019943A/ko not_active Application Discontinuation
  • 2004-09-08 WO PCT/GB2004/003829 patent/WO2005023779A1/en active Application Filing
  • 2004-09-08 AU AU2004270467A patent/AU2004270467B8/en not_active Ceased
  • 2004-09-08 BR BRPI0414236-5A patent/BRPI0414236A/pt not_active Application Discontinuation
  • 2004-09-08 PT PT04768376T patent/PT1663989E/pt unknown
  • 2004-09-08 DE DE602004020640T patent/DE602004020640D1/de active Active
  • 2004-09-08 AT AT04768376T patent/ATE428701T1/de active
  • 2004-09-08 UA UAA200602622A patent/UA85062C2/uk unknown
  • 2004-09-08 MX MXPA06002761A patent/MXPA06002761A/es active IP Right Grant
  • 2004-09-08 US US10/571,254 patent/US20060293355A1/en not_active Abandoned
  • 2004-09-08 SI SI200431145T patent/SI1663989T1/sl unknown
  • 2004-09-08 CA CA2537962A patent/CA2537962C/en active Active
  • 2004-09-08 JP JP2006525882A patent/JP2007505090A/ja active Pending
  • 2004-09-08 RU RU2006111354/04A patent/RU2363697C2/ru not_active IP Right Cessation
  • 2004-09-08 PL PL04768376T patent/PL1663989T3/pl unknown
  • 2004-09-08 EP EP04768376A patent/EP1663989B1/en active Active
  • 2004-09-08 NZ NZ545785A patent/NZ545785A/en not_active IP Right Cessation
  • 2004-09-09 MY MYPI20043667A patent/MY142615A/en unknown
  • 2004-09-10 TW TW093127580A patent/TWI370817B/zh not_active IP Right Cessation
  • 2004-09-10 AR ARP040103249A patent/AR045628A1/es unknown
  • 2004-09-18 SA SA04250297A patent/SA04250297B1/ar unknown
• 2006
  • 2006-03-02 IL IL174073A patent/IL174073A/en active IP Right Grant
  • 2006-03-14 NO NO20061181A patent/NO336358B1/no not_active IP Right Cessation
  • 2006-03-15 CO CO06026185A patent/CO5670355A2/es not_active Application Discontinuation
  • 2006-03-30 IS IS8385A patent/IS2689B/is unknown
  • 2006-09-28 HK HK06110818A patent/HK1090361A1/xx unknown
• 2009
  • 2009-06-10 HR HR20090335T patent/HRP20090335T1/xx unknown
  • 2009-06-24 CY CY20091100661T patent/CY1109173T1/el unknown
  • 2009-11-10 US US12/615,935 patent/US20100222373A1/en not_active Abandoned
• 2011
  • 2011-03-01 US US13/038,245 patent/US8436167B2/en active Active
• 2013
  • 2013-04-08 US US13/858,553 patent/US20130225622A1/en not_active Abandoned

Patent Citations (9)

Also Published As

Similar Documents

Legal Events